Pfizer Inc reported 20 holdings worth US$170M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 13, 2026
Pfizer Inc reported 20 holdings worth US$170M as of Jun 30, 2026. Largest: Allogene Therapeutics, Inc., Celcuity Inc. and Arvinas, Inc. Filed Aug 13, 2026 (Form 13F).
- Holdings
- 20
- Value as reported
- US$170M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Allogene Therapeutics, Inc. | 22M | US$46.9M | 27.5% |
| Celcuity Inc. | 296K | US$29.6M | 17.3% |
| Arvinas, Inc. | 3.46M | US$27.7M | 16.2% |
| Pyxis Oncology, Inc. | 7.03M | US$19.5M | 11.4% |
| Biohaven Ltd. | 506K | US$8M | 4.7% |
| Caribou Biosciences, Inc. | 4.69M | US$7.88M | 4.6% |
| Spero Therapeutics, Inc. | 2.36M | US$5.34M | 3.1% |
| Zentalis Pharmaceuticals, Inc. | 954K | US$3.85M | 2.3% |
| Oric Pharmaceuticals, Inc. | 373K | US$3.55M | 2.1% |
| Cardiff Oncology, Inc. | 2.41M | US$3.01M | 1.8% |
| Zura Bio Limited | 539K | US$2.88M | 1.7% |
| Bolt Biotherapeutics, Inc. | 31,305 | US$134K | 0.08% |
| Nextcure, Inc. | 44,347 | US$72,967 | 0.04% |
| Ginkgo Bioworks Holdings, Inc. | 2,928 | US$30,012 | 0.02% |
| Q32 Bio Inc. | 0 | US$0 | 0.00% |